Limits...
Integrated Treatment of Aqueous Extract of Solanum nigrum-Potentiated Cisplatin- and Doxorubicin-Induced Cytotoxicity in Human Hepatocellular Carcinoma Cells.

Wang CK, Lin YF, Tai CJ, Wang CW, Chang YJ, Choong CY, Lin CS, Tai CJ, Chang CC - Evid Based Complement Alternat Med (2015)

Bottom Line: Therefore, this study examined the tumor-suppression efficiency of AE-SN integrated with a standard chemotherapeutic drug, namely, cisplatin or doxorubicin, in human HCC cells, namely, Hep3B and HepJ5.The results suggested that the integrated treatment with AE-SN-potentiated cisplatin and doxorubicin induced cytotoxicity through the cleavage of caspase-7 and accumulation of microtubule-associated protein-1 light chain-3 A/1B II (LC-3 A/B II), which were associated with apoptotic and autophagic cell death, respectively, in both the Hep3B and HepJ5 cells.In conclusion, AE-SN can potentially be used in novel integrated chemotherapy with cisplatin or doxorubicin to treat HCC patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics and Gynecology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan ; Division of Hematology and Oncology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei 110, Taiwan ; Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan ; Department of Chinese Medicine, Taipei Medical University Hospital, Taipei 110, Taiwan.

ABSTRACT
Chemotherapy is the main approach for treating advanced and recurrent hepatocellular carcinoma (HCC), but the clinical performance of chemotherapy is limited by a relatively low response rate, drug resistance, and adverse effects that severely affect the quality of life of patients. The aqueous extract of Solanum nigrum (AE-SN) is a crucial ingredient in some traditional Chinese medicine (TCM) formulas for treating cancer patients and exhibits antitumor effects in human HCC cells. Therefore, this study examined the tumor-suppression efficiency of AE-SN integrated with a standard chemotherapeutic drug, namely, cisplatin or doxorubicin, in human HCC cells, namely, Hep3B and HepJ5. The results suggested that the integrated treatment with AE-SN-potentiated cisplatin and doxorubicin induced cytotoxicity through the cleavage of caspase-7 and accumulation of microtubule-associated protein-1 light chain-3 A/1B II (LC-3 A/B II), which were associated with apoptotic and autophagic cell death, respectively, in both the Hep3B and HepJ5 cells. In conclusion, AE-SN can potentially be used in novel integrated chemotherapy with cisplatin or doxorubicin to treat HCC patients.

No MeSH data available.


Related in: MedlinePlus

Illustration of the integrated-cell-death mechanism activated by AE-SN and either cisplatin or doxorubicin in HCC cells.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4499398&req=5

fig6: Illustration of the integrated-cell-death mechanism activated by AE-SN and either cisplatin or doxorubicin in HCC cells.

Mentions: Clear experimental evidence obtained in this study indicates that the AE-SN cotreatment potentiated cisplatin- and doxorubicin-induced cytotoxicity in human HCC cells. This AE-SN-potentiated cytotoxicity may occur through the accumulation of LC-3 A/B II and cleavage of caspase-7 to activate apoptosis and autophagic cell death in human HCC cells (Figure 6). Collectively, our results suggest that AE-SN can be used in novel integrated chemotherapy with cisplatin and doxorubicin to improve tumor-suppression efficiency in HCC treatment.


Integrated Treatment of Aqueous Extract of Solanum nigrum-Potentiated Cisplatin- and Doxorubicin-Induced Cytotoxicity in Human Hepatocellular Carcinoma Cells.

Wang CK, Lin YF, Tai CJ, Wang CW, Chang YJ, Choong CY, Lin CS, Tai CJ, Chang CC - Evid Based Complement Alternat Med (2015)

Illustration of the integrated-cell-death mechanism activated by AE-SN and either cisplatin or doxorubicin in HCC cells.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4499398&req=5

fig6: Illustration of the integrated-cell-death mechanism activated by AE-SN and either cisplatin or doxorubicin in HCC cells.
Mentions: Clear experimental evidence obtained in this study indicates that the AE-SN cotreatment potentiated cisplatin- and doxorubicin-induced cytotoxicity in human HCC cells. This AE-SN-potentiated cytotoxicity may occur through the accumulation of LC-3 A/B II and cleavage of caspase-7 to activate apoptosis and autophagic cell death in human HCC cells (Figure 6). Collectively, our results suggest that AE-SN can be used in novel integrated chemotherapy with cisplatin and doxorubicin to improve tumor-suppression efficiency in HCC treatment.

Bottom Line: Therefore, this study examined the tumor-suppression efficiency of AE-SN integrated with a standard chemotherapeutic drug, namely, cisplatin or doxorubicin, in human HCC cells, namely, Hep3B and HepJ5.The results suggested that the integrated treatment with AE-SN-potentiated cisplatin and doxorubicin induced cytotoxicity through the cleavage of caspase-7 and accumulation of microtubule-associated protein-1 light chain-3 A/1B II (LC-3 A/B II), which were associated with apoptotic and autophagic cell death, respectively, in both the Hep3B and HepJ5 cells.In conclusion, AE-SN can potentially be used in novel integrated chemotherapy with cisplatin or doxorubicin to treat HCC patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics and Gynecology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan ; Division of Hematology and Oncology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei 110, Taiwan ; Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan ; Department of Chinese Medicine, Taipei Medical University Hospital, Taipei 110, Taiwan.

ABSTRACT
Chemotherapy is the main approach for treating advanced and recurrent hepatocellular carcinoma (HCC), but the clinical performance of chemotherapy is limited by a relatively low response rate, drug resistance, and adverse effects that severely affect the quality of life of patients. The aqueous extract of Solanum nigrum (AE-SN) is a crucial ingredient in some traditional Chinese medicine (TCM) formulas for treating cancer patients and exhibits antitumor effects in human HCC cells. Therefore, this study examined the tumor-suppression efficiency of AE-SN integrated with a standard chemotherapeutic drug, namely, cisplatin or doxorubicin, in human HCC cells, namely, Hep3B and HepJ5. The results suggested that the integrated treatment with AE-SN-potentiated cisplatin and doxorubicin induced cytotoxicity through the cleavage of caspase-7 and accumulation of microtubule-associated protein-1 light chain-3 A/1B II (LC-3 A/B II), which were associated with apoptotic and autophagic cell death, respectively, in both the Hep3B and HepJ5 cells. In conclusion, AE-SN can potentially be used in novel integrated chemotherapy with cisplatin or doxorubicin to treat HCC patients.

No MeSH data available.


Related in: MedlinePlus